Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Paynova in conjunction with raising of capital and change in listing
Mandate

Vinge advises Paynova in conjunction with raising of capital and change in listing

June 07, 2022 Capital Markets and Public M&A

Vinge has advised Paynova AB, under change of name to Sileon AB, in connection with a fully subscribed rights issue valued at approximately SEK 70 million.  

In connection with the issue, Paynova has also made public their intention to implement a change of listing from NGM Regulated to Nasdaq First North Growth Market.

Vinge’s team consisted of, among others, Anders Strid, Edin Agic (project manager), Adrian Filipovic and Amelia Rihs.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026